Renewed interest in the progesterone receptor in breast cancer

[1]  E. Mallon,et al.  The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone , 2016, British Journal of Cancer.

[2]  M. Clemons,et al.  Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review , 2016, Cancer and Metastasis Reviews.

[3]  K. Gelmon,et al.  Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review , 2016, Cancer and Metastasis Reviews.

[4]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[5]  Rory Stark,et al.  Progesterone receptor modulates estrogen receptor-α action in breast cancer , 2015, Nature.

[6]  L. Pusztai,et al.  Multigene prognostic tests in breast cancer: past, present, future , 2015, Breast Cancer Research.

[7]  C. Caldas,et al.  Progesterone receptor modulates ERa action in breast cancer , 2015 .

[8]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[9]  A. Thompson,et al.  Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study , 2013, British Journal of Cancer.

[10]  Andrew H. Beck,et al.  Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype , 2013, Breast Cancer Research.

[11]  Petra Seibold,et al.  Intrinsic breast cancer subtypes defined by estrogen receptor signalling—prognostic relevance of progesterone receptor loss , 2013, Modern Pathology.

[12]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[13]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[14]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[16]  R. Dikshit,et al.  Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. van Calster,et al.  Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[19]  S. Paik,et al.  Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. , 2009, Breast.

[20]  E. van Limbergen,et al.  Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Neven,et al.  Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .

[24]  Adrian V. Lee,et al.  Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. , 2005, Journal of the National Cancer Institute.

[25]  A. Hanby.  The molecular pathology of neoplasia , 1997, Cancer and Metastasis Reviews.

[26]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Skjaerven,et al.  Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status. , 1996, Journal of clinical pathology.